134 related articles for article (PubMed ID: 10395117)
21. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
22. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
[TBL] [Abstract][Full Text] [Related]
23. Linezolid pharmacokinetics in pediatric patients: an overview.
Jungbluth GL; Welshman IR; Hopkins NK
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S153-7. PubMed ID: 14520140
[TBL] [Abstract][Full Text] [Related]
24. Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections.
Joos B; Luethy R; Muehlen E; Siegenthaler W
Am J Med; 1984 Oct; 77(4C):59-62. PubMed ID: 6093521
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
[TBL] [Abstract][Full Text] [Related]
26. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications.
Barnes KI; Little F; Smith PJ; Evans A; Watkins WM; White NJ
Clin Pharmacol Ther; 2006 Dec; 80(6):582-96. PubMed ID: 17178260
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
29. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
30. Cefotaxime kinetics in plasma and synovial fluid following intravenous administration in horses.
Orsini JA; Moate PJ; Engiles J; Norman T; Poppenga R; Benson CE; Boston RC
J Vet Pharmacol Ther; 2004 Oct; 27(5):293-8. PubMed ID: 15500566
[TBL] [Abstract][Full Text] [Related]
31. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
32. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
Ariano RE; Nyhlén A; Donnelly JP; Sitar DS; Harding GK; Zelenitsky SA
Ann Pharmacother; 2005 Jan; 39(1):32-8. PubMed ID: 15598967
[TBL] [Abstract][Full Text] [Related]
34. Accuracy of serum gentamicin concentration predictions generated by a personal-computer software system.
Robinson JD; Hatton RC; Russell WL; Klapp D; Lopez LM
Clin Pharm; 1984; 3(5):509-16. PubMed ID: 6548429
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis].
Halacová M; Průsa R; Kotaska K; Vávrová V
Cas Lek Cesk; 2004; 143(3):187-90. PubMed ID: 15134039
[TBL] [Abstract][Full Text] [Related]
36. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
Hamzeh FM; Benson C; Gerber J; Currier J; McCrea J; Deutsch P; Ruan P; Wu H; Lee J; Flexner C;
Clin Pharmacol Ther; 2003 Mar; 73(3):159-69. PubMed ID: 12621381
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol.
Murthy BP; Skee DM; Danyluk AP; Brett V; Vorsanger GJ; Moskovitz BL
Curr Med Res Opin; 2007 Feb; 23(2):275-84. PubMed ID: 17288681
[TBL] [Abstract][Full Text] [Related]
38. Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval.
Kearns GL; Young RA; Jacobs RF
Clin Pharmacokinet; 1992 Apr; 22(4):284-97. PubMed ID: 1606788
[TBL] [Abstract][Full Text] [Related]
39. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
[TBL] [Abstract][Full Text] [Related]
40. Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease.
Maksoud E; Koehl B; Facchin A; Ha P; Zhao W; Kaguelidou F; Benkerrou M; Mariani P; Faye A; Lorrot M; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
